innovation highlight
Vampire bat saliva helps acute stroke therapy
The therapeutic focus of PAION lies in the area of strokes and other thrombotic disorders. The companys drug candidate that is furthest along the pipeline is Desmoteplase, a highly selective plasminogen activator which clinical studies have shown could be safely administered up to nine hours following the onset of stroke.
Desmoteplase © Paion AG
This genetically reverse-engineered protein was originally discovered in the saliva of the vampire bat (Desmodus rotundus), whose sole source of nutrition is the blood of mammals.
The effectiveness of Desmoteplase is achieved through the selective activation of fibrin-bound plasminogen. Following activation, plasminogen is converted into the enzyme plasmin, which triggers the abruption of the thrombus by breaking down its fibrin matrix. The blood supply to the affected tissues is thus re-established and the ischemic damage that would otherwise progress further is minimized. Paion AG, www.paion.de
Kontakt:
BioRiver Life Science im Rheinland e.V.
Martin Kretschmer
kretschmer@bioriver.de
+49 (0) 211 316 0610
+49 (0) 700 246 748 37
Internet: www.bioriver.de
Source: BioRiver - Life Science im Rheinland e.V.
Print page
Back
